Biotech Values

[bellweather1]

ARRY:

Have to wonder why they would structure a trial who's size was viewed as likely insufficient to get a statistically significant primary result.

If, for example, 120 pts would be expected to make it, why not go for that? Are Kras-mutant NSCLC pts that difficult to come by? If not, the strategy appears shortsighted.

Alternatively, if Astra didn't believe that even a larger trial size had much chance of a clear benefit, why structure the trial with OS as the primary endpoint(i.e.-why set themselves up for failure)?

What am I missing here?